Quick Answer
GSK plc reported R&D Expense of $7.53 billion for fiscal year 2025.
GSK plc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.53B | +17.6% |
| 2024 | $6.40B | +2.9% |
| 2023 | $6.22B | +13.4% |
| 2022 | $5.49B | +9.3% |
| 2021 | $5.02B | +4.7% |
| 2020 | $4.79B | +4.9% |
| 2019 | $4.57B | +17.3% |
| 2018 | $3.89B | -13.0% |
| 2017 | $4.48B | +23.4% |
| 2016 | $3.63B | — |
- GSK plc showed an increase of +17.6% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, GSK plc’s r&d expense has grown by 107.4% (from $3.63 billion to $7.53 billion).
- The most recent figure is from GSK plc’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 6, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: